Cargando…
Complement protein C3a enhances adaptive immune responses towards FVIII products
The most serious complication in the treatment of hemophilia A (HA) is the development of factor (F)VIII inhibitors or antidrug antibodies (ADA) occurring in 25-35% of patients with severe HA. The immunological mechanisms underlying the development of ADA against FVIII products have not been complet...
Autores principales: | Ringler, Eva, Iannazzo, Samira Ortega, Herzig, Jessica, Weiss, Lisa M., Anzaghe, Martina, Miller, Lilija, Waibler, Zoe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230409/ https://www.ncbi.nlm.nih.gov/pubmed/36727395 http://dx.doi.org/10.3324/haematol.2022.281762 |
Ejemplares similares
-
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
por: Bou-Jaoudeh, Melissa, et al.
Publicado: (2023) -
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
por: Rossato, Paolo, et al.
Publicado: (2022) -
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study
por: Giuffrida, Gaetano, et al.
Publicado: (2022) -
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association
por: Testa, Maria Francesca, et al.
Publicado: (2022) -
APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis
por: Stritt, Simon, et al.
Publicado: (2022)